First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee(Washington University in St. Louis), Sarah Cooley(NHS Blood and Transplant), Melissa M. Berrien-Elliott(Washington University in St. Louis), Peter Westervelt(Washington University in St. Louis), Michael R. Verneris(NHS Blood and Transplant), John E. Wagner(NHS Blood and Transplant), Daniel J. Weisdorf(NHS Blood and Transplant), Bruce R. Blazar(NHS Blood and Transplant), Celalettin Üstün(NHS Blood and Transplant), Todd E. DeFor(NHS Blood and Transplant), Sithara Vivek(University of Minnesota Medical Center), Lindsey Peck(Washington University in St. Louis), John F. DiPersio(Washington University in St. Louis), Amanda F. Cashen(Washington University in St. Louis), Rachel L. Kyllo, Amy Musiek(Washington University in St. Louis), András Schaffer, Milan J. Anadkat(Washington University in St. Louis), Ilana S. Rosman, Daniel D. Miller(University of Minnesota), Jack O. Egan(Altor BioScience (United States)), Emily K. Jeng(Altor BioScience (United States)), Amy D. Rock(Altor BioScience (United States)), Hing C. Wong(Altor BioScience (United States)), Todd A. Fehniger(Washington University in St. Louis), Jeffrey S. Miller(NHS Blood and Transplant)
Cited by 406Open Access
Abstract
T cell numbers and function. This immunostimulatory IL-15 superagonist warrants further investigation to augment antitumor immunity alone and combined with other immunotherapies. This trial was registered at www.clinicaltrials.gov as #NCT01885897.
Related Papers
No related papers found
Powered by citation graph analysis